PD-1 and PD-L1 Inhibitor Market Future Business Opportunities 2023-2028 | Pfizer Inc., Novartis AG, AstraZeneca PLC
The global PD-1 and PD-L1 inhibitor market was valued at US$ 30,535.5 Mn in 2021 and is forecast to reach a value of US$ 77,541.1 Mn by 2028 at a CAGR of 14.2% between 2022 and 2028 . The global PD-1 and PD-L1 inhibitor market is experiencing strong growth due to the rise in incidence or prevalence of cancer and growing geriatric population around the world. Moreover, increase in awareness among people about immune checkpoint inhibitors is expected to boost the growth of the market. However, high cost of cancer treatment and risk of complications associated with the treatment is expected to hamper growth of the global PD-1 and PD-L1 inhibitor market. Global PD-1 and PD-L1 Inhibitor Market: Regional Insights Based on geography, the PD-1 and PD-L1 inhibitor market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. Among regions, North America is expected to gain hi...